Cagrilintide

1 Identity

Incretin and amylin receptor agonists. component of the fixed combination marketed in development as CagriSema. CAS 1415456-99-3.

Sequence

{Eicosanedioic acid-gamma-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2, with a disulfide bridge between the two cysteines (Cys3-Cys8 in the supplier's numbering, which counts the gamma-Glu as position 1; these are the 2nd and 7th amino-acid residues of the chain). THIRTY-seven residues, not 32; the 32-residue backbone figure that circulates for this molecule is wrong.

Molecular formula

C194H312N54O59S2

Average mass

4409.069 Da (C194H312N54O59S2) from the formula. Listings commonly print 4409.07.

Monoisotopic mass

4406.2515 Da neutral. Practical charge states: [M+4H]4+ m/z 1102.5702, [M+5H]5+ m/z 882.2576, [M+6H]6+ m/z 735.3825.

Salt / variant note

Adding two AEEA (8-amino-3,6-dioxaoctanoic acid) units gives C206H334N56O65S2, 4699.39 avg / 4696.3993 mono - 290.3 Da heavier than the real article. That linker architecture belongs to semaglutide-class molecules, not to cagrilintide, whose linker is gamma-Glu alone. Genuine commercial and analytical variants: (1) free base versus acetate, sold as separate catalog items by more than one institutional supplier and deposited as separate PubChem records (CID 171397054 and CID 164618153); acetate stoichiometry is written as X by those suppliers, so net peptide is undeclared at the catalog level. (2) ring-open, fully reduced material, C194H314N54O59S2, 4411.085 avg / 4408.2672 mono, +2.016 Da - and note that this number sits within 0.009 Da of PubChem's erroneous exact mass, so a certificate printing 4408.26 is indistinguishable on its face from a reduced lot. (3) free-acid C-terminus (amidation failure), C194H311N53O60S2, 4410.053 avg / 4407.2355 mono, +0.984 Da. (4) des-acyl backbone with the eicosanedioyl-gamma-Glu unit absent entirely, C169H269N53O53S2, 3955.449 avg / 3952.9425 mono, -453.62 Da. (5) near-neighbor amylins: native human amylin near 3903, pramlintide near 3949 - both within the range a low-resolution deconvolution could confuse with the des-acyl species. (6) Scrambled-disulfide and dimeric species at the same or double nominal mass.

2 Class & testing panel

Form

Single article

Testing panel

P2 — panel definition

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

A substantial sponsor-run clinical program exists and is registered. Cagrilintide has been studied by Novo Nordisk A/S in phase 1 and phase 2 trials as a single agent and in fixed combination with semaglutide, with the combination program registered on ClinicalTrials.gov under the REDEFINE series and reported in general medical journals from 2021 onward; a phase 2 report of cagrilintide monotherapy appeared in The Lancet in 2021. This is a description of what has been registered and published, by study type and sponsor. No United States marketing authorization exists for cagrilintide as a single agent as of August 2026. No pharmacopoeial monograph exists.

4 Storage & specification

Storage

Lyophilized powder, -20 degrees C plus or minus 5 degrees C, desiccated, protected from light.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C.